Exploring New Possibilities: Ascentage Pharma’s Groundbreaking Studies at AACR 2023
Ascentage Pharma Announces Positive Results from Preclinical Studies on Olverembatinib A Promising Breakthrough in Cancer Therapy Exciting news has emerged from Ascentage Pharma, a leading biopharmaceutical company, regarding the results of three preclinical studies on their novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351). This innovative therapy has shown great promise in the treatment of various types…